Hepatitis C

CarelonRx launches SpecialtyRx Savings Navigator to Enhance Affordability, Management of Specialty Medications

Retrieved on: 
Monday, April 22, 2024
Other Health, Networks, General Health, Internet, Professional Services, Pharmaceutical, Technology, Health Technology, Health Insurance, Insurance, Human Resources, Health, Paragon, Cancer, Pharmacy, Digital, Risk, Hepatitis C, Rheumatology, Elevance Health, Wealth, Research Triangle, Patient, Multiple sclerosis, Health insurance

Today, CarelonRx announced the launch of SpecialtyRx Savings Navigator, a comprehensive approach to specialty medication savings across pharmacy and medical benefits.

Key Points: 
  • Today, CarelonRx announced the launch of SpecialtyRx Savings Navigator, a comprehensive approach to specialty medication savings across pharmacy and medical benefits.
  • This solution aims to help employers plan for the specialty spend of tomorrow, while providing advocacy and care to their employees who utilize specialty medications today.
  • Using advanced analytics, CarelonRx’s SpecialtyRx Savings Navigator will identify members whose health is at the greatest risk.
  • The SpecialtyRx Savings Navigator product is now available to integrated Administrative Services Only (ASO) clients.

BLACK HEALTH MATTERS TO HOST FREE SPRING HEALTH SUMMIT AND EXPO IN WASHINGTON, D.C.

Retrieved on: 
Wednesday, April 3, 2024
Kidney, Glucose, LDL, Exercise, Hepatitis C, Jabari, Black, BMS, National Pan-Hellenic Council, Patient, Vertex, Lunch, PSA, Legislation, Education, Gallaudet University, Omega Psi Phi, Incontinence, Johnson & Johnson, Cholesterol, WRC-TV, Triglyceride, Hypertension, Sanofi, Doctor of Pharmacy, Leukemia, Memory, Food, HDL, Phi Beta Sigma, Health, COVID-19 vaccine, Conference, BHM, COVID-19, All My Children, Howard University Hospital, Breakfast, Kidney disease, Diet, Guru, Sibley Memorial Hospital, Pharmaceutical industry

WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13. As part of the award-winning health summit series, the free, one-day event will be held at the Kellogg Conference Hotel at Gallaudet University at 800 Florida Avenue, N.E., Washington, DC 20002 and includes celebrity hosts, medical professionals, health screenings, prizes, breakfast, and lunch. The event is open to the public and will begin at 8:30 a.m. with breakfast and conclude at 3:30 p.m.

Key Points: 
  • Popular health-focused event to feature free screenings, conversations with experts and celebrities
    WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13.
  • After over a decade of hosting the popular health-focused summits, this will be the first in Washington, D.C. for Black Health Matters.
  • The Black Health Matters Spring Summit & Expo is sponsored by leading health organizations including Sanofi|Regeneron, Johnson & Johnson Health Care Systems, Johnson & Johnson Innovative Medicine, Research Includes Me, BMS, Sanofi, argenx, Vertex and CISCRP.
  • Notable partners are Howard University Hospital; DC Department of Health Care Finance; Precision Wellness; and American Association of Kidney Patients.

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

Retrieved on: 
Thursday, March 7, 2024
Influenza, Hepatitis B, CDSCO, FDA, Point-of-care testing, Growth, 2005 in television, Sale, ABC, Euro starter kits, Malaria, COVID-19, Fever Dream, RT, Mycobacterium tuberculosis, HPV, Chikungunya, PCR, Hepatitis C, IVD, Vaccine

SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.

Key Points: 
  • Co-Primers utilize a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions.
  • "The importance of accurate, reliable PCR testing at the high-throughput clinical laboratory level remains critical," remarked Dwight Egan, CEO of Co-Diagnostics.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

Care Resource Receives $50,000 from Advance Auto Parts Foundation to Deliver Healthcare Services to Under-Resourced Communities in Broward County

Retrieved on: 
Tuesday, March 5, 2024
Immunization, HRSA, Transport, Language, Health education, Geography, Health, HIV, Hepatitis C, Insurance, Nursing

FORT LAUDERDALE, Fla., March 5, 2024 /PRNewswire/ -- Care Resource has launched a new mobile health unit, made possible by a generous $50,000 donation from the Advance Auto Parts Foundation.

Key Points: 
  • FORT LAUDERDALE, Fla., March 5, 2024 /PRNewswire/ -- Care Resource has launched a new mobile health unit, made possible by a generous $50,000 donation from the Advance Auto Parts Foundation.
  • This mobile health unit marks a significant advancement in the health center's mission to expand access to services in under-resourced communities throughout South Florida.
  • "Every person deserves the opportunity for a full, healthy life, which is why community health is a key pillar for our Advance Auto Parts Foundation.
  • By expanding health care services through mobile health units, Care Resource can further provide communities with the right care, at the right time, in the right place.

Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board

Retrieved on: 
Wednesday, February 28, 2024
Public policy, Gilead Sciences, EVP, Entrepreneurship, Patient, Knowledge, HIV, Hepatitis C, Pharma, Pharmaceutical industry

PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board.

Key Points: 
  • PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board.
  • "We are thrilled to have an industry icon of Jim's caliber lead our board as our company matures," said Josh Halpern , Co-Founder and CEO of IntegriChain.
  • The Board is enthusiastic about adding further expertise to build upon the Company's leadership and support the expansion of its product offerings," said Daniel Berglund, Co-Head of Healthcare, Nordic Capital Investment Advisors and Board Member of IntegriChain.
  • "I am honored to join the IntegriChain board at this pivotal moment," said Meyers.

Government of Canada supports community-based projects addressing HIV, Hepatitis C, and other sexually transmitted and blood-borne infections

Retrieved on: 
Friday, February 23, 2024
Parliament, HIV/AIDS, Infection, Syphilis, Investment, Quality of life, Harm reduction, Government, Hepatitis, Address, CAF, Risk, Public Health Agency, PHAC, Stigma, HRF, Chlamydia, Knowledge, Hepatitis C, Gonorrhea, Mental health, HIV, Public

However, these infections remain a significant public health concern in Canada, especially among Indigenous, 2SLGBTQ+, and other equity-deserving communities.

Key Points: 
  • However, these infections remain a significant public health concern in Canada, especially among Indigenous, 2SLGBTQ+, and other equity-deserving communities.
  • Today's funding includes more than $12 million through the CAF, which will support 15 community-based interventions to address HIV, hepatitis C and other STBBI.
  • In 2022, the Government of Canada invested $106.4 million to help address STBBI across Canada.
  • Through the HIV and Hepatitis C Community Action Fund, the Public Health Agency of Canada (PHAC) invests $26.4 million annually to support time-limited projects (up to 5 years) across Canada to address HIV, hepatitis C and other sexually transmitted infections (e.g., chlamydia, gonorrhea, syphilis).

Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

Retrieved on: 
Friday, February 9, 2024
Biotechnology, Professional Services, Health, Environmental Issues, General Health, Pharmaceutical, Environmental, Social and Governance (ESG), DEI (Diversity, Equity and Inclusion), Hospitals, Environment, Sustainability, Science, Carbon, Health equity, Education, Dow Jones, Capital, Culture, Medication, COVID-19, Sustainability accounting, Public opinion, ESG, Public affairs, CNBC, Task force, Gilead Sciences, Patient, Water, Social, Research, Hepatitis C, HIV

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies.
  • The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people.
  • Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.
  • Learn more about Gilead’s commitment to ESG at https://www.gilead.com/purpose/esg .

Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs

Retrieved on: 
Monday, February 5, 2024
General Health, Health, Science, Research, Oncology, COVID-19, Senior, Management development, Head, Obesity, University of Navarra, Harvard Business School, Inc., Fragile X syndrome, Doctor of Pharmacy, Janssen Pharmaceuticals, Investment, Infection, Hepatitis C, MBA, Regulatory affairs, Master of Science, Complutense University of Madrid, RSV, Acquisition, Vaccine, University, Johnson & Johnson, Pharmaceutical industry

Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.

Key Points: 
  • Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
  • He joins Shionogi Inc. from Johnson & Johnson, where he served as the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs.
  • Prior to this, Dr. Polo led the development strategy of treatments for influenza, RSV and hepatitis C at Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Dr. Polo received his PharmD, Master of Science and Ph.D. in Clinical Biochemistry from the Complutense University of Madrid in Spain.

Blue Faery Continues Its Love Your Liver Campaign During Black History Month

Retrieved on: 
Thursday, February 1, 2024
Multimedia, Liver cancer, Hepatocellular carcinoma, Black, Research, MD, Caregiver, Patient, HCC, Statistics, Hepatitis C, Black History Month, Risk, Education, Love, Fairy, Cancer, Liver disease

BIRMINGHAM, Ala., Feb. 1, 2024 /PRNewswire/ -- Black/African Americans are 50% more likely to get liver cancer than the general population, and incidence rates are climbing. The Love Your Liver campaign provides community members with convenient opportunities to learn more about their unique liver cancer risks and how to actively manage them. Type 2 diabetes and hepatitis C can both lead to liver cancer, so those in the Black/African American community who currently have or previously had one or both of those diseases are at higher risk for liver cancer. Both type 2 diabetes and hepatitis C are preventable and treatable, so education and early detection are vital to improving survival rates.

Key Points: 
  • Blue Faery is pleased to announce that its annual liver disease and cancer awareness campaign will continue in 2024 during Black History Month.
  • The Love Your Liver campaign provides community members with convenient opportunities to learn more about their unique liver cancer risks and how to actively manage them.
  • Love Your Liver Live, a Black History Month Community Event series, kicks off on February 22, 2024, at 7 p.m.
  • Blue Faery has many educational and advocacy programs, including Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

United States Connected Drug Delivery Devices Markets, Competition, Forecasts & Opportunities, 2028F - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Health, Pharmaceutical, Senior counsel, ClinicalTrials.gov, Hepatitis C, COPD, Hypertension, Research, Chronic obstructive pulmonary disease, Conditional sentence, Healthcare Facilities Accreditation Program, Asthma, Dexcom, Patient, Male, Administration, Roche, R, Growth, Hospital, Female, Diabetes, Pharmacotherapy, Tuberculosis, Pharmaceutical industry, Birth control

Improvement in the quality of patient care and compliance and the changing healthcare infrastructure is expected to boost the United States connected drug delivery devices market growth.

Key Points: 
  • Improvement in the quality of patient care and compliance and the changing healthcare infrastructure is expected to boost the United States connected drug delivery devices market growth.
  • The segment is anticipated to dominate the United States connected drug delivery devices market in the next five years.
  • Also, the awareness regarding the benefits of connected systems over the traditional drug delivery system with improved patient response is expected to accelerate the growth of the United States connected drug delivery devices market.
  • Company Profiles: Detailed analysis of the major companies present in the United States connected drug delivery devices market.